QUOTE AND NEWS
StreetInsider.com  Oct 1  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/Anthera+Pharma+%28ANTH%29+Engaged+in+Potential+Partnership+Negotiations+for+Blisibimod/9877250.html for the full story.
Benzinga  Oct 1  Comment 
Anthera Pharmaceuticals, Inc. (NASDAQ: ANTH) today confirmed it is engaged in potential partnership negotiations for blisibimod for both lupus and IgA nephropathy in territories outside the United States. Anthera does not intend to communicate...
Benzinga  Sep 17  Comment 
Universal Corp (NYSE: UVV) shares reached a new 52-week low of $46.42. Universal Corp shares have dropped 11.32% over the past 52 weeks, while the S&P 500 index has gained 15.85% in the same period. Oncolytics Biotech (NASDAQ: ONCY) shares fell...
Benzinga  Jul 14  Comment 
Anthera Pharmaceuticals, Inc. (NASDAQ: ANTH) today announced that it has acquired Sollpura (liprotamase), a novel investigational Pancreatic Enzyme Replacement Therapy ("PERT") from Eli Lilly and Company. Sollpura is a soluble, stable and...
StreetInsider.com  Jun 23  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Management+Changes/Anthera+Pharma+%28ANTH%29+Adds+Brian+Mueller+as+Director/9606087.html for the full story.
StreetInsider.com  Mar 31  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Management+Changes/Anthera+Pharma+%28ANTH%29+Adds+Steven+Engle+as+DIrector/9333775.html for the full story.
StreetInsider.com  Mar 13  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Earnings/Anthera+Pharmaceuticals%2C+Inc.+%28ANTH%29+Posts+Q4+Loss+of+48cShare/9277579.html for the full story.
Benzinga  Nov 20  Comment 
Anthera Pharmaceuticals (NASDAQ: ANTH) was accused of withholding data to academic investigators from the phase III clinical trial of the heart drug varespladib. The varespladib phase III trial consisted of 5,145 patients with acute coronary...
FierceBiotech  Nov 19  Comment 
Last year, Anthera Pharmaceuticals pulled the plug on its lead drug after the cardiovascular disease treatment ran into some insurmountable efficacy problems in Phase III but failed to mention that the now-discarded varespladib actually increased...
StreetInsider.com  Sep 25  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/Anthera+Pharma+%28ANTH%29+to+Present+Data+from+Phase+2b+PEARL-SC%2C+Open-Label+Extension/8719387.html for the full story.




 
TOP CONTRIBUTORS

Anthera Pharmaceuticals (ANTH) (NASDAQ:ANTH) is a pharmaceutical company developing drug treatments for respiratory, cardiovascular, and immunological diseases. Its current products in development are therapies for the inflammation of heart muscle, lupus, and sickle cell disease.

For pharmaceutical drugs to reach the market, it must pass three stages of FDA approval process. Anthera's lead product candidate A-002, a drug to treat symptoms of shortage of oxygen to the heart (acute coronary syndrome), has completed the second stage for FDA approval. [1] The 2009 market size is valued at $1 billion. [2]

The company's initial public offering of stock was filed on 16 September 2009 and is expected to begin trading on the week of February 22. The proposed offer price range is $13-$15. The company offered 4.6 million shares. [1]

In the FY 2009 ending 31 December 2009, it reported $11.8 million in operating expenses, down 14.8% from $13.86 million in operating expenses in 2008. The company has not incurred any revenues, and it cannot incur any revenues until it receives regulatory and commercial licenses for its products. [1]

References

  1. 1.0 1.1 1.2 Anthera S-1/A
  2. Market Research
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki